Suqin Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suqin Guo has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jianping Wu
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication - Rui Liu
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan 440070, China
1 shared publication - Si Cheng
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication - Xia Liu
School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 469
Mechanisms and Therapeutic Targets of Ischemia—Reperfusion Injury in Stroke: A Narrative Review Focusing on Blood—Brain Barrier Dysfunction
Ischemic stroke remains a leading cause of death and disability worldwide. While thrombolysis and endovascular thrombectomy are current mainstays of treatment, their clinical efficacy is often undermined by ischemia–reperfusion injury (I/R). This injury induces secondary brain damage, primarily via disruption of the blood–brain barrier (BBB). No approved therapies directly target BBB protection. This review reinterprets the pathophysiological mechanism of BBB disruption after stroke through a dynamic spatiotemporal framework. The pathological cascade reaction is clearly divided into two core stages: the ischemic phase is mainly driven by energy failure and calcium overload; the reperfusion phase is further divided into four consecutive and progressive sub-stages, namely, oxidative stress burst, amplification of inflammatory response, matrix metalloproteinase 9 (MMP-9)-mediated barrier degradation and programmed cell death. This review critically assesses current therapies and identifies major clinical translation gaps, including a temporal mismatch between preclinical and clinical windows, unacceptable toxicity, lack of durable efficacy and biphasic effects. Matching specific interventions to the different pathophysiological stages of blood–brain barrier disruption is essential for optimizing clinical outcomes.
- 27 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 469
Open AccessMechanisms and Therapeutic Targets of Ischemia—Reperfusion Injury in Stroke: A Narrative Review Focusing on Blood—Brain Barrier Dysfunction
Ischemic stroke remains a leading cause of death and disability worldwide. While thrombolysis and endovascular thrombectomy are current mainstays of treatment, their clinical efficacy is often undermined by ischemia–reperfusion injury (I/R). This injury induces secondary brain damage, primarily via disruption of the blood–brain barrier (BBB). No approved therapies directly target BBB protection. This review reinterprets the pathophysiological mechanism of BBB disruption after stroke through a dynamic spatiotemporal framework. The pathological cascade reaction is clearly divided into two core stages: the ischemic phase is mainly driven by energy failure and calcium overload; the reperfusion phase is further divided into four consecutive and progressive sub-stages, namely, oxidative stress burst, amplification of inflammatory response, matrix metalloproteinase 9 (MMP-9)-mediated barrier degradation and programmed cell death. This review critically assesses current therapies and identifies major clinical translation gaps, including a temporal mismatch between preclinical and clinical windows, unacceptable toxicity, lack of durable efficacy and biphasic effects. Matching specific interventions to the different pathophysiological stages of blood–brain barrier disruption is essential for optimizing clinical outcomes.